NCT01064115已完成1 期
A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fed Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Bio-equivalence study of Dr Reddys Laboratories Cetirizine Hydrochloride Tablets 10 mg
研究概览
简要总结
A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys laboratories with Zyrtec 10 mg of Pfizer labs in Healthy Adult Human Male Subjects Under Fed Conditions.
详细描述
Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Cross Over, and Comparative Oral Bioavailability study in healthy, adult, human, male subjects under Fed Conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males between 18 and 45 years of age (both inclusive) living in and around Ahmedabad city of western part of India.
- •Having a Body Mass Index (BMI) between 18.5 and 24.9 {both inclusive), calculated as weight in kg/height in m2
- •Not having any significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.
- •Able to comply with the study procedures, in the opinion of the investigator.
- •Able to give written consent for participation in the trial.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to cetirizine or any other related drugs.
- •Any disease or condition which might compromise the hemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •Use of any medicine within 14 days prior to start of the study. In any such case subject selection will be at the discretion of the Principal investigator / Medical expert
- •Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
- •A recent history of alcoholism (<2 years) or of moderate (180 mL/day) alcohol use, or consumption of alcohol within 48 hr prior to receiving IP.
- •Smokers, who smoke more than 10 cigarettes / day or inability to abstain from smoking during the study.
- •The presence of clinically significant abnormal laboratory values during screening.
- •Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •History of psychiatric disorders.
- •A history of difficulty in donating blood.
- •Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose of IP.
- •Note: In case, the blood loss was ≤200 mL; subject can be dosed 60 days after the blood donation.
- •A positive hepatitis screen including hepatitis B surface antigen, Anti- HCV and Anti HAV antibodies.
- •A positive test result for HIV antibody and/or syphilis.
- •The receipt of an investigational drug or product, or participation in a drug research study within a period of 90 days prior to the first dose of IP (Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study).
- •Note: If subject had participated in a study in which blood loss was ≤200 mL, subject can be dosed after completion of 60 days after the last sample of the previous study.
- •An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the IP and throughout the subjects participation in the study. In any such case subject selection will be at the discretion of the Principal lnvestigator/Medical expert.
研究组 & 干预措施
Cetirizine
Experimental
Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
干预措施: Cetirizine Hydrochloride (Drug)
Zyrtec
Active Comparator
Zyrtec Tablets 10 mg of Pfizer Labs
干预措施: Cetirizine Hydrochloride (Drug)
结局指标
主要结局
Bio-equivalence study of Dr Reddys Laboratories Cetirizine Hydrochloride Tablets 10 mg
时间窗: 2 months
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting ConditionHealthyNCT01064102Dr. Reddy's Laboratories Limited30
已完成
1 期
Absolute Oral Bioavailability of RemimazolamBioavailabilityNCT04113564Paion UK Ltd.14
已完成
1 期
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult ParticipantsHealthyNCT02117505Janssen Research & Development, LLC20
已完成
1 期
Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting ConditionsHealthyNCT01276067Ranbaxy Laboratories Limited32
已完成
1 期
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid TumoursBreast Cancer, Colorectal CancerNCT01493336Hoffmann-La Roche37